1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Exelixis, Inc.
  6. News
  7. Summary
    EXEL   US30161Q1040

EXELIXIS, INC.

(EXEL)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Exelixis to Pay $55 Million to Amend Licensing Deal With Iconic Therapeutics, Gains Full Rights to Anti-TF Antibody in XB002

01/06/2022 | 09:58am EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
EXELIXIS, INC. 1.15% 18.4 Delayed Quote.0.66%
ZYMEWORKS INC. 7.85% 6.87 Delayed Quote.-58.08%
All news about EXELIXIS, INC.
05/27EXELIXIS, INC. : Change in Directors or Principal Officers, Submission of Matters to a Vot..
AQ
05/26Exelixis Details Results of Two Cancer Trials of Cabozantinib in Combination With Pembr..
MT
05/26Exelixis Announces Detailed Results from Urothelial Carcinoma and Non-Small Cell Lung C..
BU
05/26Exelixis Announces Results from Phase 2 Trial of Cabozantinib in Combination with Pembr..
BU
05/26Exelixis, Inc. Announces Results from Phase 2 Trial of Cabozantinib in Combination with..
CI
05/17TRANSCRIPT : Exelixis, Inc. Presents at RBC Capital Markets Global Healthcare Conference, ..
CI
05/11TRANSCRIPT : Exelixis, Inc. Presents at Bank of America 2022 Healthcare Conference, May-11..
CI
05/10TRANSCRIPT : Exelixis, Inc., Q1 2022 Earnings Call, May 10, 2022
CI
05/10Exelixis Q1 Non-GAAP EPS, Revenue Higher; Reiterates 2022 Guidance
MT
05/10EXELIXIS : Q1 Earnings Snapshot
AQ
More news
Analyst Recommendations on EXELIXIS, INC.
More recommendations
Financials (USD)
Sales 2022 1 587 M - -
Net income 2022 291 M - -
Net cash 2022 1 276 M - -
P/E ratio 2022 20,6x
Yield 2022 -
Capitalization 5 902 M 5 902 M -
EV / Sales 2022 2,92x
EV / Sales 2023 2,40x
Nbr of Employees 954
Free-Float 97,7%
Chart EXELIXIS, INC.
Duration : Period :
Exelixis, Inc. Technical Analysis Chart | EXEL | US30161Q1040 | MarketScreener
Technical analysis trends EXELIXIS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Last Close Price 18,40 $
Average target price 26,45 $
Spread / Average Target 43,8%
EPS Revisions
Managers and Directors
Michael M. Morrissey President-Research & Development
Christopher J. Senner Chief Financial Officer & Executive Vice President
Stelios Papadopoulos Director
Peter Lamb Chief Scientific Officer & EVP-Scientific Strategy
Vicki L. Goodman Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capi. (M$)
EXELIXIS, INC.0.66%5 902
GILEAD SCIENCES, INC.-10.76%81 280
REGENERON PHARMACEUTICALS, INC.9.70%74 647
VERTEX PHARMACEUTICALS24.65%70 008
BIONTECH SE-35.24%40 574
WUXI APPTEC CO., LTD.-22.01%39 958